The first healthy volunteer has been dosed in a trial evaluating ISM001-055, Insilico Medicine’s artificial intelligence (AI)-discovered therapy candidate for idiopathic pulmonary fibrosis (IPF). “We are very pleased to see Insilico Medicine’s first antifibrotic [treatment] candidate entering into the clinic,” Feng Ren, PhD, Insilico’s chief strategy officer, said…
First Healthy Volunteer Dosed in Trial Testing ISM001-055 for IPF
The holidays are complicated. And getting in the holiday spirit with a chronic illness, in the dead of winter, in the middle of a pandemic, can be, well, challenging. If you are struggling to feel the magic this season, that’s OK. If you’re too exhausted or too sad to…
Cudetaxestat (BLD-0409), an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed favorable safety and tolerability in a Phase 1 trial of healthy volunteers. Developed by Blade Therapeutics, cudetaxestat is designed to block the activity of an enzyme called autotaxin that produces a pro-scarring (fibrotic) signaling molecule. This enzyme commonly…
A doctor once told me he wasn’t sure I’d survive until my 30th birthday. If I did, I’d likely be dependent on supplemental oxygen, unlike any other young adult I knew at the time. This week, I turned 34. Reflecting on my nearly six years with idiopathic pulmonary fibrosis (IPF)…
Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Under the agreement, Chiesi acquired global exclusive rights to develop and manufacture the potential antifibrotic therapy, and to market it should it be approved.
PF Warriors has partnered with online shopping site Joe & Bella to make holiday gift-giving easier for people with pulmonary fibrosis (PF) — while raising funds for the nonprofit’s mission of increasing awareness of PF and other interstitial lung diseases (ILDs). Products sold at Joe & Bella…
NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), achieves significant levels in the lungs and lowers the production of molecules that promote scarring, according to preclinical studies involving rats, the company announced. “We’re delighted with the positive readout of this data so far and it further…
Researchers have now compiled the most comprehensive molecular atlas, or roadmap, to date of healthy human lungs and their early development, leading to the identification of nearly 9,000 proteins whose production changes with age. The data, open to the public through an online platform called LungMAP, are expected to help…
Being my own advocate means having to be resilient, a trait I have come to acquire. The past two weeks have really tested me, and sparked a fierce determination on my part to obtain financial assistance to help offset expenses caused by my illness. I have been researching…
LYT-100 (deupirfenidone), an experimental oral therapy containing a similar active ingredient to Esbriet, was well-tolerated at all tested doses — and did not reach the maximum tolerated dose or MTD — in a Phase 1 trial conducted in healthy volunteers. PureTech Health, which is developing LYT-100 for…
